Alerts will be sent to your verified email
Verify Email
OXYGENTAPH
|
Oxygenta Pharma
|
Lyka Labs
|
Brooks Laboratories
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
10.1 % | 145.3 % | -23.88 % |
|
5yr average Equity Multiplier
|
-1.22 | -0.06 | 1.78 |
|
5yr Average Asset Turnover Ratio
|
1.1 | 0.64 | 0.6 |
|
5yr Avg Net Profit Margin
|
-16.74 % | -21.64 % | -23.79 % |
|
Price to Book
|
0.0 | 3.91 | 4.13 |
|
P/E
|
0.0 | 50.56 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
-56.32 Days | 16.94 Days | -10.34 Days |
|
Inventory Days
|
94.46 Days | 26.54 Days | 93.5 Days |
|
Days Receivable
|
80.66 Days | 77.33 Days | 66.75 Days |
|
Days Payable
|
174.19 Days | 133.6 Days | 179.8 Days |
|
5yr Average Interest Coverage Ratio
|
-3.11 | 0.6 | -11.84 |
|
5yr Avg ROCE
|
-80.86 % | 22.35 % | -15.03 % |
|
5yr Avg Operating Profit Margin
|
-18.99 % | 20.24 % | -13.23 % |
|
5 yr average Debt to Equity
|
-1.55 | -0.79 | 0.21 |
|
5yr CAGR Net Profit
|
-9.68 % | -47.18 % | 0.22 % |
|
5yr Average Return on Assets
|
-10.42 % | -5.63 % | -14.62 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
51.12 % | 58.16 % | 52.62 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
38.79 % | 10.37 % | -13.79 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-0.04 % | -0.72 % | 9.9 % |
|
Oxygenta Pharma
|
Lyka Labs
|
Brooks Laboratories
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|